Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients.
The effect of mazindol (AN 448) on weight and blood pressure was evaluated in a double-blind cross-over trial in 28 obese hypertensive patients, whose blood pressure was under stable control with one or more of the common antihypertensive agents--diuretics, beta-blocking drugs and methyldopa. There was a statistically significant decrease in weight, but no significant change in blood pressure (systolic and diastolic) or pulse rate during active treatment. It was considered that the drug might be of benefit to some patients, provided that they were properly motivated to adhere to the dietary regime.